2022 Our Stories - Bristol-Myers Squibb
We are the unseen explorers.
We are going deeper than any deep sea diver. And further than any astronaut ever have because there are more cells in the human body than all the stars in our galaxy.
We are discovering the universes in our bodies. While we may never summit a peak where climbing new heights to understand how to cure disease. Because we are the world's most uncharted territory, thousands of breaths and countless heartbeats a day.
We are as fragile as we are complex. So much threatens our ability to live long and fulfilling lives. And we are all fighting the same fights.
We are the administrators, the truck drivers, the scientists, and the managers. The dreamers, the thinkers, and the doers. Working so that all can be and live. All the places you go, we will go there with you. All the people you love, we love them, too.
We are using science to transform lives.
We are Bristol Myers Squibb.
Letter from our Board Chair & CEO
From our 2022 Annual Report
 |
2022 was an important year for our company, one with significant clinical and regulatory achievements that broadened our portfolio, advanced our pipeline and, importantly, delivered innovative new medicines to our patients. Despite navigating a persistent global pandemic and ongoing macro and geopolitical challenges, our employees’ dedication to our vision of transforming patients’ lives through science never wavered. Our commitment to executing against our business strategy resulted in strong operational and financial performance in 2022.”Giovanni Caforio, MD
|
Total net sales
Consistent with prior year or, an increase of 3% when excluding foreign exchange
In-line brand
YoY% growth
New product portfolio*
YoY% growth
Potential for risk-adjusted sales of $10-$13B revenues in 2025
Potential for $25B+ of non-risk adjusted revenues in 2030
Delivered strong financial
and operational
performance
Figures and data from the 2022 Annual Report
GAAP EPS1
Non-GAAP EPS1,2
3 first-in-class medicines launched
For metastatic melanoma
For obstructive hypertrophic cardiomyopathy
For moderate to severe plaque psoriasis
Year at a glance
References
*New product portfolio includes Reblozyl® (luspatercept-aamt), Inrebic® (fedratinib), Onureg® (azacitidine tablets), Zeposia® (ozanimod), Breyanzi® (lisocabtagene maraleucel), Abecma® (idecabtagene vicleucel), Opdualag® (relatlimab plus nivolumab), Camzyos® (mavacamten) and SotyktyuTM (deucravacitinib).
1 GAAP and non-GAAP EPS include the net impact of Acquired IPRD charges and licensing income of ($0.24) per share for the full year 2022. Acquired IPRD refers to certain in-process research and development (“Acquired IPRD”) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.
2 This Non-GAAP amount excludes certain costs, expenses, gains and losses and other specified items. A reconciliation of GAAP to non-GAAP measures can be found on our website at bms.com. See, “Quarterly package of financial information” available on bms.com/investors for information on the list of specified items excluded from Non-GAAP EPS.